BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (ticker: BBOT) is a blank check company formed to pursue a business combination in the oncology and life sciences sector. The company filed a Form 10-Q with the Securities and Exchange Commission on November 14, 2024, offering a quarterly update on its operations as a special purpose acquisition company. BBOT completed its initial public offering in 2024, with a stated focus on identifying therapeutics and biopharmaceutical targets in the oncology space. The filing reflects the company's continued status as a pre-combination SPAC actively seeking a qualified target. For complete sponsor details, filing history, and deal-status tracking on BBOT and thousands of other SPACs, sign up for full data on SpacDesk.